Novo Nordisk’s Strategic Pivot Gains Traction as Clinical Data and Analyst Forecast Align
Novo Nordisk divests last cell therapy asset to double down on obesity; new data shows Wegovy’s 28% weight…
Novo Nordisk’s Comeback Narrative Gains Steam from Analyst Upgrade, Clinical Data and Canadian Acc
Novo Nordisk shares surge 31% from March lows as Hedgeye forecasts 52-117% upside, fueled by oral obesity drug…
Novo Nordisk’s Clinical Win and Competitive Crossroads
Novo Nordisk’s etavopivat meets Phase 3 goals in sickle cell disease, a bright spot as shares fall 23%…
Novo Nordisk’s Clinical Win and Competitive Crossroads
Novo Nordisk’s etavopivat meets Phase 3 goals in sickle cell disease, a bright spot as shares fall 23%…
Novo Nordisk’s Clinical Edge and US Push Battle a Steep Share Decline
Novo Nordisk posts strong clinical data and expands Wegovy, yet shares are down 22% YTD. Can its May…
Novo Nordisk’s Clinical Edge and US Push Battle a Steep Share Decline
Novo Nordisk posts strong clinical data and expands Wegovy, yet shares are down 22% YTD. Can its May…
Novo Nordisk Responds to Rival Launch with Clinical Data and Subscription Model
Novo Nordisk releases head-to-head data favoring oral Wegovy over Foundayo and launches a direct-to-consumer subscription plan to retain…